BACKGROUND Left ventricular (LV) hypertrophy, a key process in human cardiac disease, results from cellular
; p < 0.001). Focal fibrosis by CMR late gadolinium enhancement did not change, but ECV increased (28.2 AE 2.9% to 29.9 AE 4.0%; p < 0.001): this was the result of a 16% reduction in matrix volume (25 AE 9 ml/m 2 to 21 AE 7 ml/m 2 ; p < 0.001) but a proportionally greater 22% reduction in cell volume (64 AE 18 ml/m 2 to 50 AE 13 ml/m 2 ; p < 0.001). These changes were accompanied by improvement in diastolic function, N-terminal pro-B-type natriuretic peptide, 6-min walk test results, and New York Heart Association functional class.
CONCLUSIONS Post-AVR, focal fibrosis does not resolve, but diffuse fibrosis and myocardial cellular hypertrophy regress. Regression is accompanied by structural and functional improvements suggesting that human diffuse fibrosis is plastic, measurable by CMR and a potential therapeutic target. We aimed to demonstrate that human myocardial fibrosis is plastic and can regress after AVR and that this regression can be measured noninvasively.
METHODS
This prospective observational cohort study was 
